92 related articles for article (PubMed ID: 29665649)
21. Expression and localization of FOXO1 in non-small cell lung cancer.
Maekawa T; Maniwa Y; Doi T; Nishio W; Yoshimura M; Ohbayashi C; Hayashi Y; Okita Y
Oncol Rep; 2009 Jul; 22(1):57-64. PubMed ID: 19513505
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer.
Zang C; Nie FQ; Wang Q; Sun M; Li W; He J; Zhang M; Lu KH
Oncotarget; 2016 Mar; 7(10):11696-707. PubMed ID: 26840083
[TBL] [Abstract][Full Text] [Related]
23. N-myc downstream regulated gene 1(NDRG1) promotes the stem-like properties of lung cancer cells through stabilized c-Myc.
Wang Y; Zhou Y; Tao F; Chai S; Xu X; Yang Y; Yang Y; Xu H; Wang K
Cancer Lett; 2017 Aug; 401():53-62. PubMed ID: 28456659
[TBL] [Abstract][Full Text] [Related]
24. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma.
Xiao GQ; Li F; Findeis-Hosey J; Hyrien O; Unger PD; Xiao L; Dunne R; Kim ES; Yang Q; McMahon L; Burstein DE
Hum Pathol; 2015 Nov; 46(11):1607-15. PubMed ID: 26297253
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance and Tumor-Suppressive Function of miR-516b in Nonsmall Cell Lung Cancer.
Zhu J; Zhang Y; Yang X; Jin L
Cancer Biother Radiopharm; 2017 May; 32(4):115-123. PubMed ID: 28514208
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
30. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
31. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
32. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2.
Huang RS; Zheng YL; Li C; Ding C; Xu C; Zhao J
Life Sci; 2018 Apr; 199():104-111. PubMed ID: 29510198
[TBL] [Abstract][Full Text] [Related]
34. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
[TBL] [Abstract][Full Text] [Related]
35. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
36. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
[TBL] [Abstract][Full Text] [Related]
37. The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy.
Checinska A; Oudejans JJ; Span SW; Rodriguez JA; Kruyt FA; Giaccone G
Anticancer Res; 2006; 26(5B):3819-24. PubMed ID: 17094407
[TBL] [Abstract][Full Text] [Related]
38. p0071 interacts with E-cadherin in the cytoplasm so as to promote the invasion and metastasis of non-small cell lung cancer.
Zhao H; Zhang D; Yang L; Wang E
Mol Carcinog; 2018 Jan; 57(1):89-96. PubMed ID: 28898462
[TBL] [Abstract][Full Text] [Related]
39. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas.
Puglisi F; Aprile G; Minisini AM; Barbone F; Cataldi P; Tell G; Kelley MR; Damante G; Beltrami CA; Di Loreto C
Anticancer Res; 2001; 21(6A):4041-9. PubMed ID: 11911289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
